Peritoneal fluid lactate dehydrogenase in ovarian cancer

David Schneider, Reuvit Halperin*, Rami Langer, Ian Bukovsky, Arie Herman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


In attempt to identify patients with ovarian carcinoma and differentiate them from patients with benign ovarian tumor or other gynecological malignancies, peritoneal fluid and serum lactate dehydrogenase (LDH) levels were measured in 51 patients: 15 with ovarian carcinoma, 15 with endometrial carcinoma, 4 with cervical carcinoma, and 17 with benign ovarian tumor. Peritoneal fluid and serum LDH levels in ovarian cancer patients were significantly higher than those in patients with benign ovarian tumor (P < 0.001) or other gynecological malignancies (P < 0.001 and P < 0.03, respectively). Yet, peritoneal fluid LDH demonstrated higher diagnostic sensitivity (87%) and greater diagnostic accuracy (90%) than serum LDH (60 and 77%, respectively) or serum CA-125 (73 and 83%, respectively). Comparing the histological types of ovarian cancer, serous cystadenocarcinoma presented higher peritoneal fluid LDH levels than endometrioid or mucinous cystadenocarcinoma. No difference in peritoneal fluid LDH was observed comparing different stages of ovarian cancer. The results suggest that peritoneal fluid LDH may be an efficient biochemical marker in diagnosis of ovarian cancer.

Original languageEnglish
Pages (from-to)399-404
Number of pages6
JournalGynecologic Oncology
Issue number3
StatePublished - Sep 1997
Externally publishedYes


Dive into the research topics of 'Peritoneal fluid lactate dehydrogenase in ovarian cancer'. Together they form a unique fingerprint.

Cite this